Immedica Pharma AB presented three-year ganaxolone data in CDD at EEC Congress

Immedica Pharma AB announced that data evaluating the long-term efficacy of ganaxolone in patients with CDKL5 deficiency disorder (CDD) was presented at the 16th European Epilepsy Congress (EEC) in Athens, Greece, September 5-9, 2026.

The poster presentation featured results from a post-hoc analysis titled "Sustained clinical efficacy of ganaxolone in CDKL5 deficiency disorder: three-year follow-up." This analysis assessed long-term seizure outcomes in patients who participated in the open-label extension phase following the pivotal study.

This presentation offers valuable insight into ganaxolone's potential role in managing CDD and its ability to provide sustained benefits for individuals with this rare genetic epilepsy condition.

CDD is a severe form of epilepsy that typically begins within the first year of life and is associated with significant developmental delays. Ganaxolone is an anti-epileptic drug candidate under development.